CADTH harmonises drug reimbursement review process
Newsletters
11 November 2020
On 30 September 2020 the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of new Procedures for CADTH Drug Reimbursement Reviews (updated on 29 October 2020), which harmonise procedures under the CADTH's drug reimbursement review pathways (Common Drug Review, pan-Canadian Oncology Drug Review and Interim Plasma Protein Product Review). Notable highlights include:
- the opportunity for drug manufacturers to comment on draft review reports;
- posting of draft recommendations for stakeholder feedback; and
- introduction of categories in the reconsideration process to promote flexibility.
For further information on this topic please contact Brandon Heard at Smart & Biggar by telephone (+1 416 593 5514) or email (brheard@smart-biggar.ca). The Smart & Biggar website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.
Author
